The Conversation (0)
Trinity Biotech Announces Q4 and Fiscal Year 2018 Financial Results
Mar. 07, 2019 08:43AM PST
Biotech InvestingTrinity Biotech (NASDAQ:TRIB) has announced its financial results for Q4 and full year ended December 31, 2018. As quoted in the press release: Point-of-Care revenues decreased from $16.8m in 2017 to $14.8m in 2018, which represents a decrease of 11.6%. This was mainly attributable to lower HIV sales in Africa due to erratic ordering patterns …
Trinity Biotech (NASDAQ:TRIB) has announced its financial results for Q4 and full year ended December 31, 2018.
As quoted in the press release:
Point-of-Care revenues decreased from $16.8m in 2017 to $14.8m in 2018, which represents a decrease of 11.6%. This was mainly attributable to lower HIV sales in Africa due to erratic ordering patterns and was contributed to by the impact of significant overstocking by one larger customer which occurred during 2017. Meanwhile, HIV sales in the USA continued to be lower due to constraints on federally funded public health programs.
Clinical Laboratory revenues were $82.2m, which is broadly flat when compared with 2017. During the year, Diabetes and Autoimmunity revenues continued their upward growth trajectory. However, this growth was offset by lower Lyme revenues due to the loss of a significant contract with one of the major clinical laboratory service providers in the USA. Revenues were also adversely impacted by foreign exchange movements and this was most pronounced in Brazil where the Real was over 14% weaker year on year.
The gross margin for the year was 42.7% compared to 42.3% in 2017. This increase was mainly attributable to cost savings implemented during the year, the benefit of which outweighed the negative impact of lower point-of-care revenues and adverse currency movements.
Research and Development expenses for the year decreased from $5.7m to $5.4m, a decrease of $0.3m. Meanwhile, Selling General and Administrative (SG&A) expenses decreased from $30m to $28.2m, a decrease of 6%. In both cases the main driver has been the impact of cost savings, though in the case of SG&A expenses a gain recognised in Q3, 2018 on a partial buyback of the company’s Exchangeable Notes was also a contributory factor.
Operating profit for the year increased from $5.5m to $6.7m in 2018. This increase was mainly attributable to lower indirect costs and to a lesser extent the increase in gross margin.